Cargando…

Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study

BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. Few studies have been published on the clinical stages of recurrent HCC. AIM: To assess the applicability of the Barcelona Clinic Liver Cancer (BCLC) st...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Si-Yang, Liang, Bin, Chen, Yuan-Yuan, Tang, Yun-Tian, Dong, Xiao-Feng, Liu, Tian-Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462222/
https://www.ncbi.nlm.nih.gov/pubmed/34621858
http://dx.doi.org/10.12998/wjcc.v9.i27.8020
_version_ 1784572159097569280
author Yao, Si-Yang
Liang, Bin
Chen, Yuan-Yuan
Tang, Yun-Tian
Dong, Xiao-Feng
Liu, Tian-Qi
author_facet Yao, Si-Yang
Liang, Bin
Chen, Yuan-Yuan
Tang, Yun-Tian
Dong, Xiao-Feng
Liu, Tian-Qi
author_sort Yao, Si-Yang
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. Few studies have been published on the clinical stages of recurrent HCC. AIM: To assess the applicability of the Barcelona Clinic Liver Cancer (BCLC) staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC. METHODS: The clinicopathological data of 81 patients with recurrent HCC who were admitted to the Hospital of Guangxi Zhuang Autonomous Region from January 2013 to December 2017 were collected. The patients were divided into three groups according to the BCLC staging system as follows: (1) Group A with BCLC stage A, 51 patients; (2) Group B with BCLC stage B, 14 patients; and (3) Group C with BCLC stage C, 16 patients. The median time to tumor recurrence and the median overall survival were compared. RESULTS: The median time to tumor recurrence in groups A, B, and C was 16 ± 1.5 mo, 10 ± 2.8 mo, and 6 ± 0.5 mo, respectively, with a statistically significant difference among them (χ(2) = 70.144, P < 0.05); no statistically significant difference was noted between group A and group B (χ(2) = 2.659, P > 0.05), although there were statistically significant differences between group A and group C and between group B and group C (χ(2 )= 62.110, and 19.972, P < 0.05). The median overall survival in groups A, B, and C were 42 ± 5.1 mo, 22 ± 3.1 mo, and 13 ± 1.8 mo, respectively, with a statistically significant difference among them (χ(2 )= 38.949, P < 0.05); there were statistically significant differences between group A and group B, group A and group C, and group B and group C (χ(2 )= 9.577, 37.172, and 7.183, respectively; P < 0.05). CONCLUSION: There are different prognoses in recurrent HCC patients according to the BCLC staging. Therefore, BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC.
format Online
Article
Text
id pubmed-8462222
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-84622222021-10-06 Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study Yao, Si-Yang Liang, Bin Chen, Yuan-Yuan Tang, Yun-Tian Dong, Xiao-Feng Liu, Tian-Qi World J Clin Cases Retrospective Cohort Study BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. Few studies have been published on the clinical stages of recurrent HCC. AIM: To assess the applicability of the Barcelona Clinic Liver Cancer (BCLC) staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC. METHODS: The clinicopathological data of 81 patients with recurrent HCC who were admitted to the Hospital of Guangxi Zhuang Autonomous Region from January 2013 to December 2017 were collected. The patients were divided into three groups according to the BCLC staging system as follows: (1) Group A with BCLC stage A, 51 patients; (2) Group B with BCLC stage B, 14 patients; and (3) Group C with BCLC stage C, 16 patients. The median time to tumor recurrence and the median overall survival were compared. RESULTS: The median time to tumor recurrence in groups A, B, and C was 16 ± 1.5 mo, 10 ± 2.8 mo, and 6 ± 0.5 mo, respectively, with a statistically significant difference among them (χ(2) = 70.144, P < 0.05); no statistically significant difference was noted between group A and group B (χ(2) = 2.659, P > 0.05), although there were statistically significant differences between group A and group C and between group B and group C (χ(2 )= 62.110, and 19.972, P < 0.05). The median overall survival in groups A, B, and C were 42 ± 5.1 mo, 22 ± 3.1 mo, and 13 ± 1.8 mo, respectively, with a statistically significant difference among them (χ(2 )= 38.949, P < 0.05); there were statistically significant differences between group A and group B, group A and group C, and group B and group C (χ(2 )= 9.577, 37.172, and 7.183, respectively; P < 0.05). CONCLUSION: There are different prognoses in recurrent HCC patients according to the BCLC staging. Therefore, BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC. Baishideng Publishing Group Inc 2021-09-26 2021-09-26 /pmc/articles/PMC8462222/ /pubmed/34621858 http://dx.doi.org/10.12998/wjcc.v9.i27.8020 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Cohort Study
Yao, Si-Yang
Liang, Bin
Chen, Yuan-Yuan
Tang, Yun-Tian
Dong, Xiao-Feng
Liu, Tian-Qi
Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study
title Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study
title_full Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study
title_fullStr Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study
title_full_unstemmed Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study
title_short Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study
title_sort clinical stages of recurrent hepatocellular carcinoma: a retrospective cohort study
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462222/
https://www.ncbi.nlm.nih.gov/pubmed/34621858
http://dx.doi.org/10.12998/wjcc.v9.i27.8020
work_keys_str_mv AT yaosiyang clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy
AT liangbin clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy
AT chenyuanyuan clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy
AT tangyuntian clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy
AT dongxiaofeng clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy
AT liutianqi clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy